Related Targets |
Target |
Mechanism ERs agonists [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date26 May 2021 |
Target |
Mechanism CD20 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD47 modulators [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Start Date05 Apr 2024 |
Sponsor / Collaborator Endeavor Health LLC [+1] |
Start Date01 Jan 2024 |
Sponsor / Collaborator |